O

ONWARD Medical NV
XBRU:ONWD

Watchlist Manager
ONWARD Medical NV
XBRU:ONWD
Watchlist
Price: 3.9 EUR -1.27% Market Closed
Market Cap: €218.4m

Wall Street
Price Targets

ONWD Price Targets Summary
ONWARD Medical NV

Wall Street analysts forecast ONWD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ONWD is 10.42 EUR with a low forecast of 8.99 EUR and a high forecast of 11.87 EUR.

Lowest
Price Target
8.99 EUR
130% Upside
Average
Price Target
10.42 EUR
167% Upside
Highest
Price Target
11.87 EUR
204% Upside
ONWARD Medical NV Competitors:
Price Targets
TEL
TE Connectivity Ltd
35% Upside
VIBHA
Vibhavadi Medical Center PCL
2% Upside

Revenue
Forecast

N/A
Past Growth
361% / Year
Estimated Growth
Estimates Accuracy
-85%
Average Miss
N/A
Past Growth
361% / Year
Estimated Growth
Estimates Accuracy
-85%
Average Miss

The compound annual growth rate of ONWARD Medical NV's revenue for the next 4 years is 361%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
9%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
9%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ONWD's stock price target?
Price Target
10.42 EUR

According to Wall Street analysts, the average 1-year price target for ONWD is 10.42 EUR with a low forecast of 8.99 EUR and a high forecast of 11.87 EUR.

What is ONWARD Medical NV's Revenue forecast?
Projected CAGR
361%

The compound annual growth rate of ONWARD Medical NV's revenue for the next 4 years is 361%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett